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The purpose of this study was to ﬁnd out what proportion of patients are referred as lung cancer guidelines assume, whether
different referral pathways result in different management and what proportion of patients are seen within recommended time
intervals between referral and treatment. A randomly selected sample of 400 lung cancer cases registered with the former
Yorkshire Cancer Registry database in 1993 was selected for casenote analysis. Mode of presentation, speciality of initial
referral, treatment by specialist, time intervals for key points in the referral pathways were analyzed. A total of 362 (90.5%) of
case-notes were available. Less than half of lung cancer patients (173, 47.8%) presented to hospital with a chest X-ray
diagnosis of lung cancer. Forty-one (11.3%) presented as self-referrals to Accident and Emergency and the remainder were
referred without a diagnosis of lung cancer by other routes, mainly via GPs. Patients who did not present initially with a lung
cancer diagnosis were less likely to receive specialist care (62%:96%), or have their diagnosis histologically conﬁrmed
(57.1%:80.3%) or receive surgery or radical radiotherapy (6.9%:13.9%). Nine per cent of all 362 patients did not receive a
specialist opinion. Eighty per cent of patients referred by a GP with CXR suspected lung cancer were seen at hospital within 2
weeks. Only 32.4% of those receiving active treatment were treated within 8 weeks of clinical diagnosis or ﬁrst hospital visit.
Lung cancer patients presenting to hospital without a suspicious CXR are less likely to have specialist care, histological
conﬁrmation of their cancer and have lower rates of active treatment (surgery, any radiotherapy or chemotherapy).
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Lung cancer is the most common cause of cancer death, and over
37000 cases are diagnosed in the UK every year (Ofﬁce for
National Statistics, ONS, 1998). The median survival in the UK
is about 5 months with overall 5-year survival in Yorkshire being
less than 6%, rising to 35% in those receiving surgical treatment
(Cancer Outcomes Monitoring, 1999) (available at www.nycris.
org.uk). Most European countries have higher survival rates (Jans-
sen-Heijnen et al, 1998). Prompt referral and good teamwork are
essential at every stage of its management. Better organized service
delivery coupled with advances in treatment have the potential to
signiﬁcantly improve standards of care.
Lung cancer treatment and referral guidelines (BTS, 1998;
NHSE, 1998; Scottish Intercollegiate Guidelines Network, SIGN,
1998; SMAC, 1994) assume that most patients will present to their
primary care physician, general practitioner (GP), with chest or
respiratory symptoms. The GP will then organize a CXR, and if
this suggests lung cancer, patients are then referred to a chest
physician with a working diagnosis of lung cancer. Clinical experi-
ence suggests that this is not always the case. Using a population
based sample of lung cancer patients we wished to identify what
proportion of patients were referred by their GP with or without
a diagnosis of lung cancer suspected and what proportion were
admitted acutely. We examined to whom patients were referred
initially and whether they received any specialist management.
We examined the time intervals between symptoms, presentation,
diagnosis, referral and treatment. Some of these issues have been
explored in Scottish patients (Kesson et al, 1998; Fergusson et al,
1999; Gregor et al, 1999, 2001). Kesson et al (1998) considered
referral times and treatment. Fergusson et al (1999) linked treat-
ment rates with seeing a chest physician. Gregor et al (1999,
2001) noted variations in management and treatment rates linked
to survival in different health board areas. Data from West London
showed a low level of specialist management of their lung cancer
patients, (Pickles and Rudolf, 1998) but little detail on referral
patterns was reported in any of these studies. The purpose of this
study was to ﬁnd out what proportion of patients are referred as
lung cancer guidelines assume, whether different referral pathways
result in different management and what proportion of patients are
seen within recommended time intervals between referral and
treatment.
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The study was designed to provide descriptive information about
the referral pathways for lung cancer and, as such, no formal
sample size calculations were made. A pilot study (based on
50 patients), undertaken in advance of this study, showed that
we could obtain information on investigation, treatment and
management from GP and hospital records. It also showed that
there were two main presentations of lung cancer (with and
without a chest X-ray diagnosis) of roughly equal proportions.
An overall sample size of 400 was therefore decided upon, with
the aim of obtaining a reasonable number of patients in each
presentation group, but also reﬂecting practical considerations.
We took a 400-patient random sample from the former York-
shire Cancer Registry (population 3.7 million) population based
database of 2456 cases of lung cancer registered as being incident
in 1993. Exclusion criteria were private treatment or cases whose
treatment was organized entirely extra-regionally. Those with
missing casenotes were excluded from the analysis.
The sample was stratiﬁed by three age groups (565, 65–75,
475) as referral and treatment patterns were likely to vary with
age (Brown et al, 1996; Nugent et al, 1997; Turner et al, 1999)
The sample was also stratiﬁed by health authority as area of resi-
dence might impact on the study (Cancer Outcomes Monitoring,
1999). After stratiﬁcation cases were randomly selected using an
Excel function. The sample sizes (number per health authority in
each age band) were chosen to be proportionate to the number
of cases presenting in each health authority during the previous
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Figure 1 Consultant referral pathways.
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randomly chosen, was representative of the patients seen in the
whole region.
From the sample selected, introductory relevant baseline infor-
mation was extracted on registration number, name, sex, age,
date of birth, GP, main hospital and area of residence from the
Cancer Registry database. The Family Health Services Authority
and primary managing hospital clinician of each of these patients
were contacted and their permission to view the casenotes
obtained. GPs were contacted in the case of living patients. Local
Research Ethics Committee approval was also sought and obtained
for each district.
The following data items were extracted from the case notes:
patient details, symptoms, management by GP, management by
all consultants at all hospitals involved, management dates, death
details and last appointment date. Tumour type was classiﬁed as
clinical where no histological conﬁrmation of lung cancer was
available. Small cell cancer included cases which had either small
cell or oat cell histology. All other histological diagnosis were clas-
siﬁed as non small cell cancer. Where an important procedure such
as bronchoscopy was not recorded, we presumed it was not
performed. Management was considered to be specialist if given
by a chest physician, thoracic surgeon or oncologist. Chest physi-
cians included those general physicians with a special interest in
chest medicine. The consultant chest physicians in the research
group identiﬁed these chest physicians, with the aid of membership
of the regional Thoracic Society.
Deﬁnitive treatment was deﬁned as surgery (pneumonectomy or
lobectomy), radical radiotherapy (radiotherapy directed at treating
lung cancer itself) and chemotherapy. Palliative treatment recorded
was palliative radiotherapy (for symptom control only), palliative
surgery or best supportive care. The difference between radical
and palliative was discerned from the notes. Only one deﬁnitive
treatment was recorded. Where more than one modality of deﬁni-
tive treatment was given surgery was recorded as the deﬁnitive
treatment, and radiotherapy and chemotherapy were adjuvant
and not recorded in the study. Radical radiotherapy (but not
palliative radiotherapy) was considered to be the deﬁnitive treat-
ment where chemotherapy was also given. All deﬁnitive
treatments up to the date of the study were recorded. Only 14
patients (3.9%) were alive at that point. Active treatment was
considered to have occurred if any deﬁnitive treatment or palliative
radiotherapy was given, but not best supportive care only.
Guidelines gave a variety of standards for referral to ﬁrst hospi-
tal visit, and referral to treatment (SMAC, 1994; Scottish
Intercollegiate Guidelines Network, SIGN, 1998; BTS, 1998). From
these we chose two speciﬁcs to report here from these guidelines.
The percentage referred within 2 weeks of GP referral, and treat-
ment within 8 weeks of ﬁrst hospital visit for the with diagnosis
group or 8 weeks of clinical diagnosis for the without or acute
diagnosis group. Presenting symptoms were noted from the GP
casenotes and the principal symptom or symptoms recorded as
such. Symptoms written down by the GP such as chestiness, bron-
chitis or chest infection were amalgamated into one heading of
chest infection. Where cases suffered from longstanding lung
disease, dating the presentation of the ﬁrst cancer symptom to
the GP, proved difﬁcult. Data were extracted from both sets of
casenotes by one trained individual and recorded on case report
forms designed speciﬁcally for the study. To ensure consistency
of recording, two researchers extracted the data from the ﬁrst 50
notes and the results were compared and found to have less than
a 5% difference in recording rate. One of these researchers was
responsible for extracting the remainder of the case note data.
Analysis was conducted using Access, Excel and SPSS programs.
The analysis was mainly descriptive but some comparisons of data
were made using w
2 tests to check for signiﬁcant differences
(P50.05) between groups and between datasets.
RESULTS
GP and hospital casenotes were traced for 362 out of 400
patients (90.5%). Eleven patients had neither set of notes. GP
notes alone were traced for a further 16 (4%) patients. Eleven
patients (2.8%) were excluded because of other reasons, ﬁve
for being private patients, three for diagnosis prior to 1992,
one for initial diagnosis in a foreign country, one for returning
to a foreign country in the year of diagnosis and one because of
lack of patient consent. The excluded patients were 29.7% female
(out of 38 cases) compared to 37.6% female in the 362 cases,
and mean age of the 27 years excluded patients with age data
was 70.4 years compared to 69.9 in the 362 cases. Characteristics
of the study patients were compared with population data from
1993 in the recent Key Sites study report for lung cancer
(Cancer Outcomes Monitoring, 1999) which provides data on
all lung cancer registrations in Yorkshire for the time period
1986–1994. This comparison found that there were no statisti-
cally signiﬁcant differences (P40.05) in patient characteristics
between the two sets of patients.
Mode of presentation
The pilot study noted two main modes of presentation for lung
cancer patients and one less common presentation. The same cate-
gorization was used for the main study. The ‘With CXR Diagnosis’
group consisted of patients who presented to their GP with a
respiratory related complaint. A GP requests a CXR and, on the
basis of an abnormal result refers the patient to hospital. There
were 173 patients (47.8%) in this group. Patients in the ‘Without
CXR Diagnosis’ group were referred to hospital because of their
symptoms but with no prior CXR. There were 148 patients
(40.9%) in this group, 49 being admitted on day of referral. The
‘Acute’ group presented themselves to Accident and Emergency.
There were 41 patients (11.3%) in this group. Patient characteris-
tics are seen in Table 1.
There is some variation between the groups in age, sex and
tumour type. Overall there are nearly twice as many men than
women. The without diagnosis group has a lower percentage of
65–75-year-olds, and a higher percentage of over 75s, but this
difference in age groups is not signiﬁcant (P=0.06). The rates of
histological conﬁrmation were far lower in the without diagnosis
and acute groups than were the with diagnosis group. There were
slightly more small cell cancers in the acute and without diagnosis
groups. The proportions in the three groups were signiﬁcantly
different (P50.001) for histological conﬁrmation and tumour type.
This difference between the with and without group became of
borderline signiﬁcance when the clinically diagnosed tumour types
were removed (P=0.052).
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Figure 2 Percentile intervals between ﬁrst hospital visit (or clinical diag-
nosis) and treatment.
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One hundred and thirty-nine (80%) of the with diagnosis group
presented to their GP with mainly lung related symptoms (cough,
chest pain or infection, haemoptysis or dyspnoea) compared to 69
(46.6%, CI: 38.4%, 55.0%) of those without a diagnosis. See Table
2 for principal presenting symptoms. This lists a patient’s main one
or two symptoms, but does not exclude them from having other
symptoms as well. Only 16 (39%, CI: 24.2%, 55.5%) of the acute
group were admitted with a respiratory complaint.
Investigation and treatment
Variation in both investigations and treatment are shown in Table
3. Rates of bronchoscopy, mediastinoscopy, surgery and ‘no treat-
ment’ were signiﬁcantly different (P50.001, P=0.008, P=0.04,
P=0.001 respectively) between the three groups. Bronchoscopy
and mediastinoscopy were much more common in the with diag-
nosis group. Other investigations or pleural cytology were more
common in different groups. The with CXR diagnosis had more
ultrasound, the without diagnosis group had more bone scans
and the acute group more pleural cytology. These differences were
signiﬁcant for ultrasound only (P=0.002 between all groups,
P=0.023 when without diagnosis and acute groups are combined)
Surgery, chemotherapy, and palliative radiotherapy were all used
most frequently in the with CXR diagnosis group, but the differ-
ence was only signiﬁcant for surgery (P=0.035). The number of
patients receiving radical radiotherapy was too small to make
meaningful comparisons. Treatment was associated with histologi-
cal conﬁrmation and tumour type. A total of 40 of 62 (64.5%)
patients with small cell cancer received chemotherapy, whilst 35
of 185 (18.9%) non small cell cancer patients received surgery or
radical radiotherapy. Only two of 115 (1.7%) patients without
histological conﬁrmation received chemotherapy or radical radio-
therapy, and 29 (25.2%) palliative radiotherapy.
Specialist management
Table 4 shows specialist management in the three groups. Only half
of all the patients were referred initially to a chest physician. Only
six (14.6%) of acute patients were admitted to the care of a chest
physician (possibly consistent with the chance of an acute medical
rota), whereas 141 (81.5%) of those with a diagnosis were referred
to a chest physician and a further nine (5.2%) to a thoracic
surgeon. Two (1.4%) patients of the without diagnosis patients
were initially referred to a medical oncologist.
Overall 284 (78.5%) of patients eventually had specialist care and
78 (21.5%) did not. In the with diagnosis group 166 (96%) had
such care whereas only 118 (62%) of the other two groups did.
Opinions were sought from specialists in a further 34 (23%) and
eight (20%) of without diagnosis and acute cases respectively.
Twenty-nine (15%) of the without diagnosis and acute groups
had no specialist care.
A total of 141 (39%) of cases were managed by one consultant.
The mode was two consultants and only 40 (11%) of patients were
managed by three. There were 70 different pathways of referral to
the ﬁnal consultant. A total of 180 (50%) of cases ﬁrst saw a chest
physician, 63 (35% of them) were then referred to a clinical oncol-
ogist, 43 (24%) to a thoracic surgeon, three (2%) to medical
oncologists and four (2%) to various other specialties. Most refer-
rals to a third consultant involved clinical oncologists, or thoracic
surgeons when the ﬁrst consultant was not a specialist in lung
cancer. Figure 1 and Table 5 summarize the pathways.
Referral and management intervals
Table 6 shows referral and management interval percentiles in the
three groups. Fifty per cent of patients in the with diagnosis group
were referred within 1 week of a CXR request and had their ﬁrst
hospital visit within 17 days. Eighty per cent (134) of the with
diagnosis patients were seen within 2 weeks of referral by a GP.
Seventy-one per cent (55 of 78) of those referred by a GP without
diagnosis who were not admitted as an emergency on that day
were seen within 2 weeks. Median time from ﬁrst visit to any treat-
ment was 35 days in the with diagnosis group and median time
from clinical diagnosis to treatment was 28 days for the without
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Table 2 Principal presenting symptoms
a
With diagnosis Without diagnosis Acute
Symptoms n % n % n %
Cough 57 32.9 16 10.8 1 2.4
Chest pain 26 15.0 16 10.8 3 7.3
Chest infection 26 15.0 14 9.5 1 2.4
Shortness of breath 22 12.7 24 16.2 8 19.5
Haemoptysis 18 10.4 7 4.7 3 7.3
Weight loss 12 6.9 14 9.5 0 0
Other pain 7 4.0 23 15.5 6 14.6
Other (non respiratory) 17 9.8 44 29.7 19 46.3
aSome patients had more than one principal presenting symptom.
Table 1 Patient characteristics of the three groups
All cases With diagnosis Without diagnosis Acute
Factor n % n % n % n %
Sex Male 226 62.4 105 60.7 97 65.5 24 58.5
Female 136 37.6 68 39.3 51 34.5 17 41.5
Age group (years) 565 96 26.5 44 25.4 41 27.7 11 26.8
65–75 153 42.3 85 49.1 49 33.1 19 46.3
75+ 113 31.2 44 25.4 58 39.2 11 26.8
Histological conﬁrmation Yes 247 68.2 139 80.3 87 58.8 21 51.2
No 115 31.8 34 19.7 61 41.2 20 48.8
Tumour type
a Non small cell 185 51.1 112 64.7 60 40.5 13 31.7
Small cell 62 17.1 27 15.6 27 18.2 8 19.5
Clinical 115 31.8 34 19.7 61 41.2 20 48.8
Total cases in each Per cent in each group of 362 100 173 47.8 148 40.9 41 11.3
group of all cases
aSmall cell cancer included both small cell and oat cell cancer. All other histological diagnoses were classiﬁed as non small cell cancer. Clinical
cases had no histological conﬁrmation.
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more quickly in all groups, with a median of 17 days when
recorded in the notes. Thirty-seven patients (10.2%) received deﬁ-
nitive treatment. Only 37.5% (9 of 24) of the with diagnosis group
received deﬁnitive treatment within 8 weeks of ﬁrst hospital visit
and only 23.1% (3 of 13) of the acute and without diagnosis group
were treated within 8 weeks of clinical diagnosis. The difference
between the groups is not signiﬁcant (P=0.515).
DISCUSSION
We have found no previous population-based studies looking
directly at referral patterns for lung cancer despite most guide-
lines assuming a referral pathway to hospital that includes a
CXR ordered by a general practitioner. We found that less than
50% of patients present in this fashion. A similar sample of
patients in Glasgow found 57% were initially referred to chest
physicians including some in whom the diagnosis was inciden-
tally found on chest X-ray (Kesson et al, 1998). An all
Scotland study found 58% referred initially to chest physicians
which is higher than in our data (Gregor et al, 1999). Neither
of these studies considered referral pathways and CXR use in
detail. One local UK audit noted the dispersal of patients to
many disciplines (Pickles and Rudolf, 1998), and a Royal College
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Table 4 Specialist management
All cases With diagnosis Without diagnosis Acute
n % n % n % n %
Speciality of initial referral or admitting consultant
Chest physician 180 49.7 141 81.5 33 22.3 6 14.6
Thoracic surgeon 9 2.5 9 5.2 0 0.0 0 0
General medicine 54 14.9 12 6.9 30 20.3 12 29.3
Medicine for the elderly 58 16 8 4.6 45 30.4 5 12.2
General surgery 15 4.1 2 1.2 10 6.8 3 7.3
Other 46 12.7 1 0.6 30 20.3 15 36.6
Specialist management
Managed by a specialist 284 78.5 166 96.0 93 62.8 25 61
Opinion given but not managed by a specialist 46 12.7 4 2.3 34 23.0 8 19.5
No specialist management or opinion 32 8.8 3 1.7 21 14.2 8 19.5
No. of managing consultants
1 141 39.0 62 35.8 64 43.2 15 36.6
2 180 49.7 93 53.8 71 48.0 16 39
3 40 11.0 17 9.8 13 8.8 10 24.4
4 1 0.28 1 0.6 0 0.0 0 0.0
Total cases in each group 362 100 173 47.8 148 40.9 41 11.3
Table 3 Investigation and treatment in the groups
All cases With diagnosis Without diagnosis Acute
n % n % n % n %
Investigations
Bronchoscopy 259 71.5 147 85.0 89 60.1 23 56.1
Mediastinoscopy 18 4.97 15 8.7 2 1.4 1 2.4
CT Scan 147 40.6 75 43.4 55 37.2 17 41.5
Ultrasound 107 29.6 61 35.3 43 29.1 3 7.3
Bone scan 66 18.2 29 16.8 34 23.0 3 7.3
Pleural cytology 20 5.5 8 4.6 9 6.1 3 7.3
Treatment
Surgery 32 8.8 22 12.7 9 6.1 1 2.4
RT-radical 5 1.4 2 1.2 2 1.4 1 2.4
Chemotherapy 44 12.2 23 13.3 16 10.8 5 12.2
RT-palliative 107 29.6 59 34.1 37 25.0 11 26.8
Palliative surgery 4 1.1 4 2.3 0 0.0 0 0.0
None 170 47.0 63 36.4 84 56.8 23 56.1
Total cases in each group 362 100 173 47.8 148 40.9 41 11.3
Table 5 Consultant referral pathways
Consultant First Second Third
Chest physicians 180 39 1
Thoracic surgeons 9 62 5
Oncologists–mainly clinical 2 (2 MO) 104 (2 MO) 35
Medicine for the elderly 58 8 0
Medicine 54 4 0
Other medical specialities
a 16 1* 0
Surgery 15 0 0
Other surgical specialities
b 28 2 0
None 0 142 321
Total 362 362 362
aOther medical specialities were cardiology, endocrinology, gastroenterology, haema-
tology, palliative care* and rheumatology.
bOther surgical specialities were A&E, ENT,
neurosurgery, oral surgery, orthopaedics and urology.
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British Journal of Cancer (2002) 86(1), 36–42 ã 2002 The Cancer Research Campaignof Physicians audit noted that 62% of patients were referred by
GPs to chest physicians, and that these patients had better survi-
val at 6 months (Thompson et al, 1999). However the latter
study was conﬁned to patients who underwent bronchoscopy.
Surgical treatment was only 5% in the Kesson study (Kesson
et al, 1998), but 11.6% in the later Gregor study (Gregor et
al, 1999, 2001), compared to 8.8% in our study and 10.6% in
the wider Yorkshire study (Cancer Outcomes Monitoring,
1999). In comparison to our 47% with no active treatment,
and 48.1% in the all Yorkshire study, 38.4% of the Gregor study
had supportive care only (with a further 20% with unknown
management), and 42.2% received no active treatment in the
Gregor study. It is likely that our results are generalizable across
the UK but not necessarily to other countries. Our stratiﬁed
sample of 400 (362 cases with both casenotes) comes from a
population based cancer registry. The diversity of the Yorkshire
population helps to ensure generalizability. Our sample is
comparable in age, sex, district of residence, histology and treat-
ment to that involving an 8-year retrospective study of lung
cancer from the same database using a total of 22000 cases,
2456 of which were registered in 1993 (Cancer Outcomes Moni-
toring, 1999).
Different ways of presentation to hospital are associated with
different rates of investigations, treatment and management of
patients. Variation in investigation and treatment rates have been
noted previously but not compared with routes of referral
(Fergusson et al, 1996; Gregor et al, 1999; Richardson et al,
2000) The proportion of patients without a histological diagnosis
has been proposed as an indicator of the proportion of patients
not amenable to optimal treatment, which can be used to
compare different registry populations (Crawford and Atherton,
1994). It is not certain to what extent these different types of
management are due to variation in casemix. The three groups
had no signiﬁcant differences in age and sex but tumour types
were signiﬁcantly different. This difference in tumour type could
be due to casemix with some tumours such as small cell present-
ing more acutely and less in the classical manner. It may be due
to the signiﬁcantly different and lower histological conﬁrmation
rates in the acute and without groups, but histological conﬁrma-
tion is likely to be lower in cases with poor functional status.
Fergusson et al (1999) found patients referred to a chest physi-
cian were younger and at an earlier stage. We have little
information on stage of disease or co-morbidity at presentation.
The numbers of patients recorded to have distant metastases in
each group are not signiﬁcantly different but recording of metas-
tases in casenotes is poor, particularly those metastases occurring
in lymph nodes, and many patients are in the unknown cate-
gory. Lower surgery rates might suggest that the without
diagnosis and acute group presented later, but the with diagnosis
group also has higher rates of palliative radiotherapy. An alterna-
tive possibility is that investigation and treatment differed
because these patients had less specialist care than the with diag-
nosis group (62% compared to 96%). In three previous studies
radical treatments were more likely in those reviewed by a chest
physician (Brown et al, 1996; Muers and Haward, 1996; Fergus-
son et al, 1999).
The referral times varied widely between cases and groups.
Reassuringly 80% of GP referred patients with a CXR diagnosis
were seen within 2 weeks, long before the current 2 week initia-
tive (DoH, 1997, 1999). This is similar to the ﬁndings of a
retrospective survey of English Trusts using 1997 data, (Spurgeon
et al, 2000), and with the Glasgow study (Kesson et al, 1998). Of
concern is that 67.6% of patients given radical treatment (surgery
and radical radiotherapy) did not receive this within the
suggested guideline (Scottish Intercollegiate Guidelines Network,
SIGN, 1998; SMAC, 1994) time of within 8 weeks of their ﬁrst
hospital visit (with diagnosis group) or within 8 weeks of clinical
diagnosis (other groups); but this data does predate these guide-
lines. This interval is longer than in the retrospective survey
(Spurgeon et al, 2000) which has a median time of 39 days,
but the numbers of lung cancer cases for 1 month in England
are less than expected in that study. Decisions not to treat were
taken quickly. It is not certain what caused these delays to treat-
ment. It may be that investigations were slow in arrangement or
reporting or that there were long waiting lists for suitable treat-
ment such as radical radiotherapy or surgery. Long times to
treatment have been noted by others (Billing and Wells, 1996;
Dische et al, 1996; Kesson et al, 1998). The delays experienced
by lung cancer patients are long in relation to the short median
survival of 5 months of these patients (Cancer Outcomes Moni-
toring, 1999), and longer than those for most other common
cancers. Further detail on the study may be found in the full
NYCRIS report (Cancer Outcomes Monitoring, 2000).
There is a common assumption that lung cancer patients present
to hospital with a CXR suspicious of lung cancer. We found that
over 50% of cases did not present this way. Clinicians in hospital
and general practice should be more aware of the diversity of
presentations of lung cancer. All patients with suspected lung
cancer should be referred to a member of the lung cancer team,
usually a chest physician. The intervals between management
events such as time to referral or treatment should be audited
and avoidable delays reduced to a minimum. It is of concern that
lung cancer patients presenting to hospital without a suspicious
CXR are less likely to have specialist care, histological conﬁrmation
of their cancer and that they have lower rates of active treatment
(surgery). Whether this is because of more advanced disease or
their different patterns of care urgently needs to be determined.
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Table 6 Referral and management interval specialities
Intervals given in days
First symptoms
to ﬁrst
hospital visit
GP CXR
request to
referral
GP CXR
request to ﬁrst
hospital visit
GP referral
to ﬁrst
hospital visit
With diagnosis percentiles
Number 167 146 150 167
Median 29 7 17 7
95th 118 22 49 28
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